n-palmitoylsphingosine has been researched along with Benign Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, H; Feng, SS; Gao, J; Guo, S; Jiang, J; Kou, G; Li, B; Li, J; Li, W; Niu, F; Song, H; Su, X; Wang, X; Yang, K; Yin, C | 1 |
Chan, M; Fuks, Z; GarcĂa-Barros, M; Haimovitz-Friedman, A; Hambardzumyan, D; Kaag, M; Kolesnick, R; Stancevic, B; Truman, JP | 1 |
2 other study(ies) available for n-palmitoylsphingosine and Benign Neoplasms
Article | Year |
---|---|
Co-delivery of doxorubicin and PEGylated C16-ceramide by nanoliposomes for enhanced therapy against multidrug resistance.
Topics: Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Ceramides; Doxorubicin; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Glucosyltransferases; Humans; Liposomes; Mice; Neoplasms; Polyethylene Glycols; Up-Regulation | 2015 |
Endothelial membrane remodeling is obligate for anti-angiogenic radiosensitization during tumor radiosurgery.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Apoptosis; Cattle; Cell Line, Tumor; Ceramides; Disease Models, Animal; Endothelium; Female; Humans; Male; Mice; Mice, Knockout; Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Sphingomyelin Phosphodiesterase; Vascular Endothelial Growth Factor A | 2010 |